Takeda Pharmaceutical Company Limited

Douglas Robert Cary

Hiroshi Banno

Takaharu Hirayama

Jun Fujimoto

Koji Ono

Yasuhiro Hirata

Masahiro Ito

Toshio Tanaka

Daisuke Tomita

Satoru Matsuda

Shinichi Imamura

Hidekazu Tokuhara

Yasuyoshi Arikawa

Hironobu Maezaki

Masanori Okaniwa

Yasuhiro Imaeda

Nobuki Sakauchi

Nobuo Cho

Moriteru Asano

Ryo Mizojiri

Akinori Toita

Xin Liu

Takuto Kojima

Yuya Oguro

Hironori Kokubo

Naoki Tomita

Nao Morishita

Shigeo Kajii

Ken Tsuchida

Ryujiro Hara

Yasutomi Asano

Terufumi Takagi

Osamu Kurasawa

Yusuke Tominari

Naoki Iwamura

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I):

Nitrogen containing heterocycles as CDK12 inhibitors

Provided is a compound that may have a superior CDK12 inhibitory action and is expected to be useful as a prophylactic or therapeutic drug for cancer and the like. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic compound

Provided is a heterocyclic compound that may have a GCN2 inhibitory action, and is expected to be useful for the prophylaxis or treatment of GCN2 associated diseases including cancer and the like. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

The present invention provides a heterocyclic compound having a CDK8 and/or CDK19 inhibitory effect. The present invention provides a compound represented by formula (I) (in the formula, the symbols are as defined in the description) or a salt thereof.

The present invention provides a fused heterocyclic compound that has CDK 8 and/or CDK 19 inhibitory activity. The present invention provides a compound represented by formula (I) (wherein the symbols are as defined in the description) or a salt thereof.

Fused heterocyclic compound

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q, Q, Qand Qare each a hydrogen atom or a substituent; Qand Q, and Qand Q, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y, Yand Yare each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y, and Yand Y, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z, Zand Zare each H or a substituent, or a salt thereof.

Cyclopropaneamine compound

Growing community of inventors

Fujisawa, Japan

Douglas Robert Cary